Who are Plan B (Levonorgestrel)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Natazia, Faslodex, Ortho Evra, Elocon, Gynorest, Progesterone.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/plan-b-levonorgestrel.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-09 · How we verify

Plan B (Levonorgestrel) — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Plan B (Levonorgestrel) (Plan B (Levonorgestrel)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Progestin; emergency contraceptive. Area: Contraception / Reproductive Health.

marketed Progestin; emergency contraceptive Progesterone receptor Contraception / Reproductive Health Small molecule Live · refreshed every 30 min

Target snapshot

Plan B (Levonorgestrel) (Plan B (Levonorgestrel)) — University of Pennsylvania. Levonorgestrel is a synthetic progestin that prevents pregnancy primarily by inhibiting or delaying ovulation.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Plan B (Levonorgestrel) TARGET	Plan B (Levonorgestrel)	University of Pennsylvania	marketed	Progestin; emergency contraceptive	Progesterone receptor
Natazia	DIENOGEST	Mochida Pharmaceutical Co., Ltd.	marketed	Progestin	Progesterone receptor	2010-01-01
Faslodex	fulvestrant	AstraZeneca	marketed	Estrogen Receptor Antagonist [EPC]	Progesterone receptor	2002-01-01
Ortho Evra	NORELGESTROMIN		marketed	Estrogen [EPC]	Progesterone receptor	2001-01-01
Elocon	MOMETASONE FUROATE	Merck & Co.	marketed	Corticosteroid	Progesterone receptor	1987-01-01
Gynorest	DYDROGESTERONE	Solvay	marketed	dydrogesterone	Progesterone receptor	1982-01-01
Progesterone	Progesterone plus HCG	Dunamenti REK Istenhegyi IVF Center	marketed	Progesterone [EPC]	progesterone receptor, luteinizing hormone/choriogonadotropin receptor	1978-01-01

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2026-11-29 — Elocon · 7544192 · Method of Use · US
2027-06-12 — Elocon · 8025635 · Formulation · US
2028-01-30 — Natazia · 8153616 · US
2031-10-03 — Elocon · 10357640 · Method of Use · US
2032-02-08 — Elocon · 8763222 · Formulation · US
2034-02-14 — Faslodex · 10188663 · Formulation · US
2034-02-14 — Faslodex · 9833459 · Formulation · US
2034-03-13 — Elocon · 10406332 · Formulation · US
2034-05-17 — Faslodex · 9271990 · Formulation · US
2034-11-24 — Elocon · 10232152 · Formulation · US

Sponsor landscape (Progestin; emergency contraceptive class)

University of Pennsylvania · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Plan B (Levonorgestrel) — Competitive Intelligence Brief. https://druglandscape.com/ci/plan-b-levonorgestrel. Accessed 2026-06-09.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing